Nasdaq · Biotech stocks database
RGEN (Repligen Corporation) stock: $176.89, $8.65B market cap, $810.4M cash, $8.39B EV, $10.51B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
| Cash | $810.4M |
|---|---|
| Debt | $551.0M |
| Net cash | $259.4M |
| Enterprise value | $8,394.6M |
| Basic shares | 56.4M shares |
| Fully diluted shares | 59.4M shares |
| Fully diluted market cap | $10,505.6M |
| Cash per share | $14.37 |
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Loading RGEN daily closes…